Nanotechnology Now - Press Release: ULURU Inc. Reports Second Quarter 2007 Results

Home > Press > ULURU Inc. Reports Second Quarter 2007 Results

Abstract:
ULURU INC. reported financial results today for the quarter and six months ended June 30, 2007.

ULURU Inc. Reports Second Quarter 2007 Results

ADDISON, TX | Posted on August 13th, 2007

For the quarter ended June 30, 2007, the net loss attributable to common stockholders was $1,209,000, or $0.02 per share, compared to a net loss of $1,612,000, or $0.13 per share, for corresponding period in 2006. For the six months ended June 30, 2007, the net loss was $2,056,000, or $0.03 per share, compared to a net loss of $4,530,000, or $0.38 per share, for the six months ended June 30, 2006. The net loss was impacted by non-cash expenses related to stock options accounted for in accordance with SFAS 123(R) "Share Based Payment" of $119,000 and $221,000, for the quarter and six months ended June 30, 2007, respectively (compared with no expense for the corresponding periods in 2006), and by the amortization of our intangible assets of $269,000 and $534,000 for the quarter and six months ended June 30, 2007, respectively.

Income Statement

Revenues for the second quarter of 2007 were $119,000, compared with $312,000 for the same period last year. The decrease of $193,000 is primarily due to lower licensing fees as a result of a non-recurring milestone of $155,000 for Zindaclin(R) in 2006 and the lack of Aphthasol(R) product sales to our domestic distributor in 2007 due to timing of product orders. These items were partially offset by an increase in royalties associated with the international sales of Zindaclin(R) along with an increase in sponsored research.

Total costs and expenses increased by $216,000 in the second quarter 2007 to $1,533,000, compared with the corresponding period in 2006 where total costs and expenses were $1,317,000. General and administrative expenses were responsible for this increase, as these expenses increased from $463,000 in the second quarter 2006 to $694,000 in 2007, a $231,000 increase. Increased costs include legal expenses for patent prosecution ($82,000), and expenses related to being a public company, including director fees ($71,000), annual report and annual meeting expenses ($31,000). Research and development costs increased from $478,000 in the second quarter 2006 to $554,000 in 2007. The $76,000 increase is primarily due to fees payable to the Food and Drug Administration of $58,000 and increased compensation expense of $30,000. Cost of product sales declined by $97,000 in 2007 reflecting no shipments to our distributor in the 2007 period.

Interest and miscellaneous income increased significantly in second quarter 2007 to $206,000, compared with $3,000 for the same period last year. The increase of $203,000 is attributable to our increased liquidity due to the recapitalization of the Company in December 2006.

There was no interest expense for the three months ended June 30, 2007 as compared to the expense of $610,000 for the same period last year. The decrease in interest expense relates to the payoff in December 2006 of our outstanding secured convertible debentures.

Balance Sheet

Cash and cash equivalents totaled $16,261,000 at June 30, 2007, a decrease of $657,000 as compared to our cash and cash equivalents at December 31, 2006 of $16,918,000. The decrease in net cash for the six months ended June 30, 2007 was due to several factors: the expenditure of $531,000 for the purchase of manufacturing equipment for commercial scale-up of our OraDisc(TM) products, the $350,000 payment in April 2007 of our original asset purchase obligation, and the net cash used for operations of approximately $51,000. These net cash decreases were partially offset by proceeds of $275,000 from the exercise of warrants to purchase our common stock.

Commenting on the quarterly results, Kerry P. Gray, President and CEO stated, "Our loss from operations was significantly lower than our operating plan despite our revenues being marginally lower than our expectations due primarily to sponsored research payments. Expense control and the development of study plans that offer the best potential returns on our research investment have contributed to this positive variance. We expect our operating expenses to increase over the balance of this year as we expand our organization and clinical study program to take advantage of our product opportunities."

Since the last quarterly report there has been significant progress both in the area of business development and in product development:

-- Three corporate development agreements have been signed.
* A consumer products agreement
* A veterinary products agreement
* An advanced wound care agreement

-- Clinical studies of our wound dressing product have commenced

-- Our clinical study program has been expanded to include studies in
chronic wounds with the VA Hospitals.

-- Two additional product formulations have been developed:
* In conjunction with a partner we have developed a nanoparticle spray
film
* We have expanded our wound care product line to include a preformed
sized wound dressing with the same properties as our powder
formulation

-- We have initiated a porcine study to determine the optimal material
characteristics for the clinical development of a range of dermal
fillers that we anticipate will provide longer periods between
re-application.

Gray continued, "The Company made significant business development and technical advances in the second quarter which exceeded our expectations. In addition to the announced agreements great progress has been made in numerous high value areas to expand our partnering network. The technical achievements provide us with additional opportunities for product candidates and the ability to make further improvements in our wound dressing. The preformed wound dressing product offers a convenient alternative to our powder product for various wound types and provides for additional drug delivery opportunities which we feel has exciting potential to expand our market opportunity."

####

About ULURU Inc
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating) relating to future product and financial performance of ULURU Inc. (the "Company" expected increases in our operating expenses and business development and technical advances. When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements including without limitation statements relating to the progress of our technology with corporate partners favorably impacting 2007 performance, pre-clinical results for our products and advantages of our products. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. The Company cautions that various factors, including the factors described hereunder and those discussed in the Company's other filings with the Securities and Exchange Commission, as well as general economic conditions, industry trends, collect accounts receivable, hire and retain qualified personnel, Food and Drug Administration regulations, adverse litigation, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements of the Company made by or on behalf of the Company. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. New factors emerge from time to time, and it is not possible for management to predict all of such factors. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by us with the Securities and Exchange Commission.

                                  ULURU Inc.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                 (Unaudited)

                            Three Months Ended        Six Months Ended
                                 June 30,                  June 30,
                             2007        2006         2007         2006
    REVENUES
    License fees           $16,831     $155,037     $154,880     $155,037
    Royalty income          81,456       69,943      136,918      252,115
    Product sales                0       75,578            0       75,578
    Other                   20,501       11,664      210,501       96,656
    Total Revenues         118,788      312,222      502,299      579,386

    COSTS AND EXPENSES
    Cost of goods sold           0       96,520            0       96,520
    Research and
     development           553,755       477,725   1,119,163      954,121
    General and
     administrative        693,588       462,878   1,288,826      745,907
    Amortization           268,630       262,550     534,173      519,724
    Depreciation            17,173        17,173      33,877       31,898
    Total Costs and
     Expenses            1,533,146     1,316,846   2,976,039    2,348,170

    OPERATING (LOSS)    (1,414,358)   (1,004,624) (2,473,740)  (1,768,784)

    Other Income (Expense)
    Interest and
     miscellaneous
     income                205,825         2,830     419,630       11,210
    Interest expense             0      (610,461)     (1,574)    (984,464)
    Commitment fee -
     Standby Equity
     Agreement                   0             0           0   (1,787,940)

    NET (LOSS)         $(1,208,533)  $(1,612,255)$(2,055,684) $(4,529,978)


    Basic and diluted
     net (loss) per
     common share           $(0.02)      $(0.13)      $(0.03)      $(0.38)

    WEIGHTED AVERAGE
     NUMBER OF COMMON
     SHARES
     OUTSTANDING        61,916,935   12,844,311   61,326,745   11,937,440



                                  ULURU Inc.
              SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA

                                     March 31, 2007    December 31, 2006
                                       (Unaudited)         (Audited)

    Cash and cash equivalents          $16,260,910        $16,918,007
    Current assets                      16,799,292         17,856,476
    Property and equipment, net          1,182,199            691,132
    Other assets                        11,591,298         12,119,618
    Total assets                        29,572,789         30,667,226

    Current liabilities                  1,323,997          1,382,003
    Long term liabilities - deferred
     revenue                               523,005                  0
    Total liabilities                    1,847,002          1,382,003
    Total stockholders' equity          27,725,787         29,285,223

For more information, please click here

Contacts:
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: